1. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension
- Author
-
Jean-Michel Luccarini, Christophe Guignabert, Irena Konstantinova, Sonia Pezet, Jérémy Sadoine, Jean-Louis Junien, Pierre Broqua, Yannick Allanore, Anne Cauvet, Thomas Guilbert, Ly Tu, and Jérôme Avouac
- Subjects
0301 basic medicine ,Agonist ,Genetically modified mouse ,Pathology ,medicine.medical_specialty ,medicine.drug_class ,Hypertension, Pulmonary ,Pulmonary Fibrosis ,Immunology ,Mice, Transgenic ,Fos-Related Antigen-2 ,Pulmonary Artery ,Vascular Remodeling ,Pharmacology ,Bleomycin ,Severity of Illness Index ,General Biochemistry, Genetics and Molecular Biology ,PPAR agonist ,Vascular remodelling in the embryo ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Rheumatology ,Transforming Growth Factor beta ,Pulmonary fibrosis ,Animals ,Immunology and Allergy ,Medicine ,Benzothiazoles ,Myofibroblasts ,Cell Proliferation ,030203 arthritis & rheumatology ,Sulfonamides ,Lung ,business.industry ,Fibroblasts ,medicine.disease ,Pulmonary hypertension ,Disease Models, Animal ,Treatment Outcome ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,business - Abstract
ObjectiveTo evaluate the antifibrotic effects of the pan-peroxisome proliferator-activated receptor (PPAR) agonist IVA337 in preclinical mouse models of pulmonary fibrosis and related pulmonary hypertension (PH).MethodsIVA337 has been evaluated in the mouse model of bleomycin-induced pulmonary fibrosis and in Fra-2 transgenic mice, this latter being characterised by non-specific interstitial pneumonia and severe vascular remodelling of pulmonary arteries leading to PH. Mice received two doses of IVA337 (30 mg/kg or 100 mg/kg) or vehicle administered by daily oral gavage up to 4 weeks.ResultsIVA337 demonstrated at a dose of 100 mg/kg a marked protection from the development of lung fibrosis in both mouse models compared with mice receiving 30 mg/kg of IVA337 or vehicle. Histological score was markedly reduced by 61% in the bleomycin model and by 50% in Fra-2 transgenic mice, and total lung hydroxyproline concentrations decreased by 28% and 48%, respectively, as compared with vehicle-treated mice. IVA337 at 100 mg/kg also significantly decreased levels of fibrogenic markers in lesional lungs of both mouse models. In addition, IVA337 substantially alleviated PH in Fra-2 transgenic mice by improving haemodynamic measurements and vascular remodelling. In primary human lung fibroblasts, IVA337 inhibited in a dose-dependent manner fibroblast to myofibroblasts transition induced by TGF-β and fibroblast proliferation mediated by PDGF.ConclusionWe demonstrate that treatment with 100 mg/kg IVA337 prevents lung fibrosis in two complementary animal models and substantially attenuates PH in the Fra-2 mouse model. These findings confirm that the pan-PPAR agonist IVA337 is an appealing therapeutic candidate for these cardiopulmonary involvements.
- Published
- 2017